Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies

Journal of Cardiovascular Electrophysiology

Volumn 23, Issue 3, 2012, Pages 296-301

  Baquero, Giselle A ^a   Banchs, Javier E ^a   Depalma, Sondra ^a   Young, Sallie K ^a   Penny Peterson, Erica D ^a   Samii, Soraya M ^a   Wolbrette, Deborah L ^a   Naccarelli, Gerald V ^a   Gonzalez, Mario D ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

antiarrhythmic drug; dofetilide; heart failure; implantable cardioverter defibrillator; sudden cardiac death; ventricular tachycardia

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DOFETILIDE; SOTALOL;

ADULT; AGED; ARTICLE; CATHETER ABLATION; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART EJECTION FRACTION; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; MALE; PRIORITY JOURNAL; SUDDEN DEATH;

AGED; ANTI-ARRHYTHMIA AGENTS; CARDIOMYOPATHY, DILATED; CORONARY ARTERY DISEASE; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC COUNTERSHOCK; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PHENETHYLAMINES; RECURRENCE; STROKE VOLUME; SULFONAMIDES; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION; VENTRICULAR FUNCTION, LEFT;

EID: 84858619669     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2011.02183.x     Document Type: Article

References (26)

1. Pinski SL, Fahy GJ,: The proarrhythmic potential of implantable cardioverter defibrillators. Circulation 1995; 92: 1651-1664.
2. Herrmann C, von zur Mühen F, Schaumann A, Buss U, Kemper S, Wantzen C, Gonska BD,: Standarized assessment of psychological well-being and quality-of-life in patients with implanted defobrilators. Pacing Clin Electrophysiol 1997; 20: 95-103. (Pubitemid 27053879)
3. Runsio M, Kallmer A, Kallmer G, Rosenqvist M, Bergfeldt L,: Myocardial injury after electrical therapy for cardiac arrhythmias assessed by troponin-T release. Am J Cardiol 1997; 79: 1241-1245.
4. Moss AJ, Hall WJ, Cannom DS,: W. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361: 1329-1338.
5. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, Reddy RK, Marchlinski FE, Yee R, Guarnieri T, Talajic M, Wilber DJ, Fishbein DP, Packer DL, Mark DB, Lee KL, Bardy GH,: Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008; 359: 1009-1017.
6. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL,: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781-788.
7. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K, Champagne J, Talajic M, Coutu B, Gronefeld GC, Hohnloser SH,: Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of beta blockers, amiodarone plus beta blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: The OPTIC study: A randomized trial. JAMA 2006; 295: 165-171. (Pubitemid 43076435)
8. Dorian P, Borggrefe M, Al-Khalidi HR, Hohnloser SH, Brum JM, Tatla DS, Brachmann J, Myerburg RJ, Cannom DS, van der Laan M, Holroyde MJ, Singer I, Pratt CM,: SHock Inhibition Evaluation with azimiLiDe (SHIELD) Investigators Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation 2004; 110: 3646-3654. (Pubitemid 39665252)
9. Yuan S, Wohlfart B, Rasmussen HS, Olsson S, Blomström-Lundqvist C,: Effect of dofetilide on cardiac repolarization in patients with ventricular tachycardia. A study using simultaneous monophasic action potential recordings from two sites in the right ventricle. Eur Heart J 1994; 15: 514-522. (Pubitemid 24160702)
10. Banchs JE, Wolbrette DL, Samii SM, Penny-Peterson ED, Patel PP, Young SK, Gonzalez MD, Naccarelli GV,: Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter. J Interv Card Electrophysiol 2008; 23: 111-115.
11. Pinter A, Akhtari S, O'Connell T, O'Donnell S, Mangat I, Korley V, Ahmad K, Posan E, Newman D, Dorian P,: Efficacy and safety of dofetilide in the treatment of frequent ventricular tachyarrhythmias after amiodarone intolerance or failure. J Am Coll Cardiol 2011; 57: 380-381.
12. Bazett HC,: An analysis of the time-relations of electrocardiograms. Heart 1920; 7: 353-370.
13. Pedersen OD, Bagger H, Keller N, Marchant B, Køber L, Torp-Pedersen C,: Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001; 104: 292-296. (Pubitemid 32666950)
14. Sweeney MO, Sherfesee L, DeGroot PJ, Wathem MS, Wilkoff BL,: Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm 2010; 7: 353-360.
15. Stevenson WG, Wilber DJ, Natale A, Jackman WM, Marchlinski FE, Talbert T, Gonzalez MD, Worley SJ, Daoud EG, Hwang C, Schuger C, Bump TE, Jazayeri M, Tomassoni GF, Kopelman HA, Soejima K, Nakagawa H,: Multicenter Thermocool VT Ablation Trial Investigators. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: The multicenter thermocool ventricular tachycardia ablation trial. Circulation 2008; 118: 2773-2782
16. Bokhari F, Newman D, Greene M, Korley V, Mangat I, Dorian P,: Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: Eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation 2004; 110: 112-116. (Pubitemid 38924577)
17. Køber L, Bloch Thomsen PE, Møller M, Torp-Pedersen C, Carlsen J, Sandøe E, Egstrup K, Agner E, Videbaek J, Marchant B, Camm AJ,: Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: A randomized trial. Lancet 2000; 356: 2052-2058. (Pubitemid 32009820)
18. Bashir Y, Thomsen PE, Kingma JH, Møller M, Wong C, Cobbe SM, Jordaens L, Campbell RW, Rasmussen HS, Camm AJ,: Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Am J Cardiol 1995; 76: 1040-1044
19. Simon RD, Sturdivant JL, Leman RB, Wharton JM, Gold MR,: The effect of dofetilide on ventricular defibrillation thresholds. Pacing Clin Electrophysiol 2009; 32: 24-28.
20. Boriani G, Lubinski A, Capucci A, Niederle R, Kornacewicz-Jack Z, Wnuk-Wojnar AM, Borggrefe M, Brachmann J, Biffi M, Butrous GS,: Ventricular Arrhythmias Dofetilide Investigators. A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. Eur Heart J 2001; 22: 2180-2191. (Pubitemid 33139464)
21. Stigler SM,: Regression toward the mean, historically considered. Statistical Methods in Medical Research 1997; 6: 103-114. (Pubitemid 127570358)
22. A comparison of antiarrhythmic-durg therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The antiarrhythmics versus Implantable Defibrilators (AVID) Investigators. N Engl J Med 1997; 337: 1576-1583.
23. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M,: Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335: 1933-1940. (Pubitemid 26428217)
24. Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, Daubert JP, McNitt S, Andrews ML, Elkin AD,: Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) Research Group. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 2004; 110: 3760-3765. (Pubitemid 40023973)
25. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH,: Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237. (Pubitemid 40110811)
26. Mazur A, Anderson ME, Bonney S, Roden DM,. Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: A placebo-controlled, implantable cardioverter-defibrillator-based evaluation J Am Coll Cardiol 2001; 37: 1100-1105. (Pubitemid 32217613)